Curis Inc (CRIS) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Curis reported revenue of $9.4M, down 13.4% from $10.9M the year before. Net income was -$7.6M (a -80.3% net margin), or -$11.60 per diluted share. Gross margin was -348.4% and operating margin was -60.5%. Operating activities generated -$27.2M of cash, leaving -$27.2M of free cash flow. At fiscal year end, Curis held $20.0M in total assets against $14.5M in total liabilities, including $5.1M of cash and equivalents.
Open the full interactive Curis financials → Quarterly statements, key ratios, valuation history and price charts.
Curis Key Stats
| Share Price | $0.61 |
|---|---|
| Market Cap | $1.3M |
| Revenue YoY Growth | -13.4% |
| 52-Week Range | $0.61 – $32.60 |
| Shares Outstanding | 2.1 million (basic, 2026 Q2) |
Curis Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $10.8M | $10.6M | $10.2M | $10.0M | $10.9M | $9.4M |
| Cost of Goods Sold | $35.7M | $52.7M | $63.2M | $58.4M | $55.5M | $42.3M |
| Gross Profit | -$24.9M | -$42.1M | -$53.0M | -$48.3M | -$44.5M | -$32.9M |
| Operating Income | -$24.9M | -$42.1M | -$53.0M | -$48.3M | -$44.5M | -$5.7M |
| Pre-Tax Income | -$29.9M | -$45.4M | -$56.7M | -$47.4M | -$43.4M | -$7.6M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$29.9M | -$45.4M | -$56.7M | -$47.4M | -$43.4M | -$7.6M |
| Diluted EPS | -$12.20 | -$10.00 | $12.20 | -$179.20 | -$137.60 | -$11.60 |
Curis Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $3.2M | $1.1M | $0 | $0 |
| Net Income | -$7.7M | $19.4M | -$24.2M | -$8.6M |
| Diluted EPS | -$9.80 | $1.47 | -$25.00 | -$4.02 |
Curis Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $129.6M | $40.0M | $19.7M | $26.7M | $20.0M | $5.1M |
| Current Assets | $172.8M | $122.4M | $92.1M | $60.9M | $26.4M | $6.9M |
| Total Assets | $204.4M | $162.3M | $108.8M | $77.3M | $41.3M | $20.0M |
| Current Liabilities | $10.1M | $13.4M | $10.0M | $13.5M | $19.0M | $14.1M |
| Total Long-Term Debt | $557,000 | — | — | — | $7.6M | — |
| Total Liabilities | $73.7M | $71.6M | $62.3M | $57.6M | $47.3M | $14.5M |
| Shareholders' Equity | $130.7M | $90.7M | $46.6M | $19.7M | -$6.0M | $5.5M |
Curis Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$25.7M | -$37.6M | -$54.3M | -$38.4M | -$39.6M | -$27.2M |
| Cash From Investing | -$49.0M | -$47.9M | $33.0M | $37.8M | $29.4M | $2.5M |
| Cash From Financing | $188.8M | -$4.2M | $867,000 | $7.6M | $3.4M | $9.8M |
| Free Cash Flow | -$26.4M | -$37.6M | -$54.7M | -$38.4M | -$39.6M | -$27.2M |
Figures from Curis' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Curis financials page for every line item.
Curis Company Profile
| Ticker | CRIS |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Lexington, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001108205 |
Frequently Asked Questions
What was Curis' revenue in fiscal 2025?
Curis (CRIS) reported revenue of $9.4M for fiscal 2025.
What is Curis' annual revenue history?
Curis' annual revenue by fiscal year: 2020: $10.8M; 2021: $10.6M; 2022: $10.2M; 2023: $10.0M; 2024: $10.9M; 2025: $9.4M.
What was Curis' net income in fiscal 2025?
Curis reported net income of -$7.6M for fiscal 2025.
What was Curis' earnings per share (EPS) in fiscal 2025?
Curis' diluted EPS was -$11.60 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Curis generate in fiscal 2025?
Curis generated -$27.2M of free cash flow in fiscal 2025.
What was Curis' revenue last quarter?
In its most recent reported quarter (2026 Q2), Curis reported revenue of $0.
How many shares of Curis are outstanding?
Curis reported a weighted average of 2.1 million basic shares outstanding in 2026 Q2.
What is Curis' market cap?
Based on its latest closing price, Curis (CRIS) has a market capitalization of about $1.3M.
When does Curis' fiscal year end?
Curis' fiscal year end, as registered with the SEC, is December 31.
Where is Curis headquartered?
Curis lists its business address in Lexington, Massachusetts in its SEC filings.
Curis Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →